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Abstract
Cancer genomes frequently contain somatic copy number alterations (SCNA) that can significantly perturb the expression
level of affected genes and thus disrupt pathways controlling normal growth. In melanoma, many studies have focussed on
the copy number and gene expression levels of the BRAF, PTEN and MITF genes, but little has been done to identify new
genes using these parameters at the genome-wide scale. Using karyotyping, SNP and CGH arrays, and RNA-seq, we have
identified SCNA affecting gene expression (‘SCNA-genes’) in seven human metastatic melanoma cell lines. We showed that
the combination of these techniques is useful to identify candidate genes potentially involved in tumorigenesis. Since few
of these alterations were recurrent across our samples, we used a protein network-guided approach to determine whether
any pathways were enriched in SCNA-genes in one or more samples. From this unbiased genome-wide analysis, we
identified 28 significantly enriched pathway modules. Comparison with two large, independent melanoma SCNA datasets
showed less than 10% overlap at the individual gene level, but network-guided analysis revealed 66% shared pathways,
including all but three of the pathways identified in our data. Frequently altered pathways included WNT, cadherin
signalling, angiogenesis and melanogenesis. Additionally, our results emphasize the potential of the EPHA3 and FRS2 gene
products, involved in angiogenesis and migration, as possible therapeutic targets in melanoma. Our study demonstrates the
utility of network-guided approaches, for both large and small datasets, to identify pathways recurrently perturbed in
cancer.
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Introduction
Somatic copy number alterations (SCNA) are a recurrent
characteristic of malignant cancers [1,2,3]. The amplification and
subsequent over-expression or, conversely, deletion and loss of
expression of key regulators of cell proliferation, senescence or
death have been shown in many cases to contribute significantly to
the progression from the normal to the malignant state [4,5,6,7].
Therefore, the discovery and characterization of chromosomal
regions involved in SCNA and of the genes encoded in them has
been a crucial contributor to our understanding of the molecular
mechanisms of carcinogenesis.
The methods used to detect and characterize SCNA have
evolved significantly over the last decades. Initial cytogenetic
observations have been supplemented with Southern blots and
quantitative PCR. Almost twenty years ago, the availability of
BAC clones delineating a tiling path through the entire human
genome made it possible to detect SCNA in a genome-wide
fashion, but with limited resolution [8]. More recently, oligonu-
cleotide-based arrays have enabled comparative genome hybrid-
izations (CGH) at high resolution, and CGH has become the
method of choice to detect copy-number variations [9,10,11]. A
recent SNP-based survey [1] of 3,131 copy-number profiles
derived from over 26 different types of cancer has provided a
dramatic illustration of the power of high-throughput techniques
in distinguishing random alterations in the genome from those that
may have a direct impact on tumorigenesis.
Genomic alterations in many tumors, especially at late stages in
their development, are so extensive that the copy-number status of
individual genes or chromosomal regions can vary over a very
wide range of values. A mixture of chromosomal rearrangements
and focal expansions can create genomic landscapes that are very
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exact boundaries of SCNA or the expression status of the genes
encoded within them are usually not known, precluding a
thorough assessment of their impact on the phenotype of the
cancer cells. It has recently been proposed that SNP arrays may be
better suited for the determination of copy number states in tumor
samples because the analysis of data derived from such arrays can
make use of allelic imbalance information in addition to
hybridization intensity [12].
In the present study, we analyzed the genome-wide copy-
number status of seven highly aneuploid metastatic melanoma cell
lines and determined the expression of their genes using a
sequencing-based approach. We show that a combination of SNP-
based and CGH arrays is necessary to obtain a reliable estimate of
the true copy-number status of the entire genome in the face of
extensive genomic instability, and that the combination of copy-
number and expression status provides powerful clues as to the
possible role of genes encoded within SCNA in tumorigenesis.
Moreover, we show that a protein-based network-guided analysis
of SCNA-affected genes with altered expression in our data and
two published datasets [13,14] identifies pathways commonly
altered in melanoma.
Results
CGH and SNP arrays are required to comprehensively
document somatic copy-number alterations in
metastatic melanoma cell lines
We analyzed seven low-passage melanoma cell lines that were
established from metastases (see Table 1) together with matched
controls from the same patients (see Materials and Methods).
Karyotyping of the melanoma cell lines revealed extreme levels of
aneuploidy. For example, LAU-Me280, the most extensively
deleted line, had a per cell content of 34 to 42 chromosomes
(median: 40), whereas LAU-Me275, one of the most amplified
melanomas, harbored 68 to 81 chromosomes (median 73.5) (see
Fig. 1). Additionally, the presence of many unassigned chromo-
somal fragments (markers) made it difficult to determine the true
level of aneuploidy.
In initial CGH (Agilent 244k) experiments we observed that in
LAU-Me275, and other highly hyperploid cell lines, the
hybridization ratios between cancer cells and matched controls
did not reflect the chromosome-wide aberrations observed in the
karyotypes. For example tetraploid regions were measured as
triploid or less by the CGH arrays (see Fig. S1). We considered
whether this was due to the normalization protocol and
subsequent segmentation analysis. Using technical replicates of
LAU-Me275 DNA, we tested three independent normalization
schemes, two of which were specifically developed for cancer
genome analysis (see Materials and Methods) and found that the
methodology proposed by Chen and colleagues [15] was the most
reproducible (Spearman correlation 0.96; see Fig. S2). We then
partitioned the genome into regions reflecting copy number
changes and assigned copy number using two independent
classification methods (see Materials and Methods). Since neither
of these classification methods gave entirely satisfactory results (see
Fig. S4 and Methods S1), we developed a Gaussian Mixture
Model (GMM) approach that was highly reproducible based on a
technical replicate analysis (Spearman correlation 0.9).
The GMM method found only 42 regions in the LAU-Me275
genome that were amplified (CN$4; see Table 2). This number
was less than expected based on the karyotype analysis, which
documented a high number of arm-level chromosome amplifica-
tions (see Fig. 1). Thus, while CGH-based methods are well
adapted to document differences in copy number status between
the genomes of normal cells derived from different individuals, our
results clearly show that they are inadequate to deal with the large-
scale rearrangements and amplifications typical of hyperploid
cancer cells. The most likely reason is that the total DNA content
of cancer cells is too different from that of normal cells to allow a
robust experimental normalization. Given this limitation, we asked
whether SNP arrays might be better suited to detect chromosome-
wide changes in a highly amplified genome.
We hybridized DNA from LAU-Me275 to Illumina 1M SNP
arrays and analyzed the signals using the OverUnder algorithm
[16], which uses minor allele frequencies in heterozygous loci to
improve copy number estimation. These results correlated well
(Spearman correlation 0.77) with a technical replicate analyzed on
the Affymetrix SNP platform (see Fig. S5C and S5D), and
indicated that 18,251 genes in the LAU-Me275 genome had a
copy number of at least four (see Table 2). Within this group, 132
genes had undergone focal amplifications of at least 10-fold. These
SNP-based results were more consistent with the karyotype
observations. For example, CGH had predicted two copies of
chromosome 7p (Chr7p) and three copies of Chr7q (see Fig. 2),
while the SNP results indicated three and five copies, respectively
(see Fig. 2 and 3), which was more consistent with the cytogenetic
data (see Fig. 1).
Therefore, based on our findings with LAU-Me275, we
determined the SCNA in the six other melanoma cell lines using
both CGH (Agilent 244k) and SNP (Illumina 1M) array platforms.
Identification of genes within amplifications or deletions was
determined as described in Materials and Methods, and the
number of SCNA for each cell line is given in Table 2. In all cases
CGH predicted more deletions than did SNP arrays, agreeing with
our initial observations using LAU-Me275. Also, with the
Table 1. Melanoma cell lines.
Melanoma Site BRAF mutation Number of chromosomes (karyotype)
LAU-Me280.R.LN Lymph node G593M, L597R 34–42
LAU-Me246.M1 Skin V600E 45–82
LAU-T618A Skin wt but NRAS mutation (Q61R) 55–71
LAU-T50B Skin V600E 65–71
LAU-T149D Visceral V600E 68–81
LAU-Me275 Lymph node V600E 68–81
LAU-Me235 Skin K601E 73–103
doi:10.1371/journal.pone.0018369.t001
SCNA and Gene Expression in Metastatic Melanoma
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predicted by SNP arrays. This bias is evident in a graphical
representation of the intersection between CGH and SNP
predictions (see Fig. S7) and with CGH/SNP genome-wide copy
number profiles (see Fig. S8). These results confirmed our
conclusion that CGH is more suitable for detecting deletions
while SNP arrays are better for identifying amplifications.
Few SCNA-genes are recurrent in different melanoma cell
lines
A potential problem with SCNA studies performed in isolation
is that they cannot assess the expression status of the genes
contained within the altered genomic regions. Amplified genes are
not necessarily highly expressed, and the exact boundaries of
deletions may or may not encompass a gene of interest. We
reasoned that the combination of precise copy number determi-
nation and gene expression measurement would allow us to
highlight with much higher confidence those genes whose
expression is affected by SCNA (SCNA-genes) in the melanoma
cell lines. We therefore analyzed gene expression in each of the
melanoma cell lines by RNA-seq using the Roche/454 pyrose-
quencing method. Additionally, we performed RNA-seq on a pool
of epidermal melanocytes to determine a reference level of
expression for each gene in normal melanocytic cells (see Materials
and Methods).
We first looked for genes within focal amplifications with at least
two-fold over-expression relative to the reference melanocytes (see
Table S1). Only KIAA0090, a protein coding gene of unknown
function not previously associated with cancer, was affected in
three melanomas (see Table S2). A further 56 genes were altered
in two melanomas, but the only known cancer-related gene was
MDM2, an oncogene previously demonstrated to be amplified in
sarcoma, glioma, colorectal and other cancers including melano-
ma [5,17]. In LAU-Me275, MDM2 was 3.9-fold over-expressed
relative to melanocytes and had a copy number greater than ten
(as predicted by SNP array). By contrast, in LAU-T50B, MDM2
was predicted by SNP array to be diploid (CN=2), and by CGH
to be duplicated (CN=3). This potential difference between these
cell lines is intriguing because they were derived from metastases
surgically removed from the same patient at a 12 year interval. We
Table 2. Number of genes affected by SCNA in seven melanoma cell lines.
CGH arrays LAU-Me280 LAU-Me246 LAU-T618A LAU-T50B LAU-T149D LAU-Me275 LAU-Me235 Unique gene count
Deletion 3668 4281 986 3656 108 122 1059 10711
Arm-level amplification 222 0 549 99 998 42 0 1884
Focal amplification 0 0 0 26 379 0 4 409
SNP arrays LAU-Me280 LAU-Me246 LAU-T618A LAU-T50B LAU-T149D LAU-Me275 LAU-Me235 Unique gene count
Deletion 2294 3157 2 113 70 2 39 5544
Arm-level amplification 0 0 16584 1033 3477 16398 10384 19496
Focal amplification 213 0 978 438 894 1853 161 4055
Number of genes affected by somatic deletions, arm-level amplifications ($4 copies but ,1 copy above the chromosome arm baseline) and focal amplifications ($4
copies and $1 copy above the chromosome arm baseline), as measured using SNP or CGH arrays.
doi:10.1371/journal.pone.0018369.t002
Figure 1. Karyotypes of two malignant melanomas. Representative karyotype (Giemsa stain) for LAU-Me275, one of the most hyperploid
melanoma (here 76 chromosomes including 7 markers); and LAU-Me280, the most extensively deleted line (42 chromosomes including 5 markers).
doi:10.1371/journal.pone.0018369.g001
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in these two samples using fluorescent in situ hybridization (FISH).
In LAU-Me275, the fluorescence signal indicated that at least 8
MDM2 copies were present at the locus on Chr12 in addition to a
homogeneously staining region on Chr5 (see Fig. 3A and 3B)
which is in agreement with results from the SNP arrays. In LAU-
T50B, FISH revealed a total of four MDM2 copies, two on Chr12
and two located on an unidentified chromosome (see Fig. 3C and
3D), which is higher than the copy number estimated by CGH
and SNP arrays. Re-investigation of the raw SNP data for LAU-
T50B showed that there was indeed a small amplification signal at
MDM2, but this had not been detected using our optimization
parameters (see Methods S1). This highlights the challenge of
determining optimal parameters that are usable on a genome-wide
scale for all samples in a study.
We next derived a list of genes within deletions detected by
CGH that were expressed in melanocytes but not in the melanoma
cell lines (see Table S1). We reasoned that such genes are likely to
be enriched for melanocyte functions that have been lost during
tumorigenesis. The vast majority of such genes (554) were private
to a single melanoma sample; seventy genes were shared by two
samples; and only ten genes were shared by three melanomas:
ADAMTSL1, ARMC4, DLL1, HSD17B3, LOC441177, OSTCL,
PARK2, PLXDC2, SLC24A2 and ULBP3 (see Table S2).
Altogether, we identified a total of 1,710 SCNA-genes affected
by amplification or deletion (summarized in Table S2; complete
dataset in Table S3). To determine the relevance to melanoma of
this set of altered genes from our small sample set, we compared it
to gene lists in two published studies that used larger melanoma
collections [13,14]. These two studies provided a list of genes
recurrently affected by amplification or deletion in 76 (primary
and metastatic) and 60 (metastatic) melanoma samples, respec-
tively. Only 196 of our 1,089 amplified genes (p-value,0.001, see
Fig. 4A), and 17 of our 634 genes within deletions (p-value,0.007,
see Fig. 4B) were present in the Stark and Hayward or Gast et al.
datasets. Surprisingly, the number of genes common to the two
published gene sets was also small (27 amplified genes and 2 genes
within deletions; p-values,0.005), and demonstrates the difficulty
to identify commonly affected genes relevant to tumor progression
even within larger melanoma collections.
Correlation between mRNA and protein levels
A potential problem with assessing gene expression by mRNA
quantitation is that this may not reflect cellular protein levels. To
check whether SCNA-genes were also expressed at the protein
level in the melanoma cell lines, we performed a SILAC proteomic
analysis (stable isotope labeling with amino acids in cell culture
[18,19]). This technique is used to quantify relative protein
amounts as measured by mass spectrometry in extracts from cells
grown in unlabeled (light) medium and cells grown in (heavy)
medium containing non-radioactively-labeled amino acids. Since
the normal human melanocytes did not grow well in the labeling
media, heavy isotopes were incorporated into the Lau-Me275 cell
line, and protein quantification in all cases was relative to this
Figure 2. Copy number analysis using CGH and SNP arrays. A. and B. shows the analysis of LAU-Me275 on CGH and SNP arrays. C. and D.
shows results for LAU-Me280. Probe/SNP are plotted as a function of their genomic position on the X axis. Y axis for CGH arrays corresponds to
hybridization ratios. Y axis for SNP arrays corresponds to the predicted copy number. Colors indicate a copy number state (orange,2 copies; gray=2
copies; cyan=3 copies; dark blue.3 copies). Dark gray in the CGH panels indicates regions identified as diploid in the analysis, but where the
karyotype analysis indicated copy neutral or deleted states, possibly due to cell heterogeneity.
doi:10.1371/journal.pone.0018369.g002
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we investigated whether transcript levels reflected protein levels as
detected by SILAC. As shown in Fig. S11 there was a moderate
but significant correlation between global mRNA and protein
levels in all samples (mean Spearman correlation 0.62).
Pathways significantly enriched in SCNA-genes are
recurrent in melanoma
As described above, we found that very few of the SCNA-genes
were altered in more than one melanoma cell line, which is not
unexpected given the small number of samples in our dataset. An
idea popular in the current literature is that signaling pathways,
rather than individual genes, are recurrently perturbed in cancer
[20]. To determine whether the SCNA-genes from different
melanoma cell lines shared membership of one or more cellular
pathways, we investigated whether the proteins encoded by the
SCNA-genes were connected in known human protein interaction
networks (see Materials and Methods). Out of a total of 1,563
proteins analyzed, 377 (24%) were connected within the network,
and clustering of the proteins based on the topology of the sub-
networks identified 14 protein networks, or ‘clusters’, containing at
least five significantly connected members. For each cluster, we
identified genes belonging to known signaling and metabolic
pathways including nine clusters that significantly overlapped
known pathways (FDR#0.05; listed in Table S4). Following
detailed manual annotation, the resulting pathways were ranked
according to the number of contributing melanomas and to the
number of SCNA-genes involved in the pathway. The pathways
common to at least four melanoma samples are shown in Table 3
(for the complete list see Table S4). Interestingly, the vast majority
of the recurrent pathways we identified involve signal transduction
and have been implicated in one or more cancer types. In
addition, that we identified ten pathways common to at least five
of the melanoma samples confirms the idea that protein network-
guided analysis is a good method for detecting recurrently affected
pathways in small datasets.
In our search for genes recurrently affected by SCNA, we found
only ,10% overlap between our list of SCNA-genes and those
derived from studies with much larger sample sizes [13,14]. To
determine if this was also true at the level of pathways, we
performed a protein network-guided analysis as described above
on each of these datasets using the published gene lists (neither
study originally presented this type of analysis). Detailed
annotation and comparison of the results for each dataset is given
in Table S4. In contrast to what we had found at the gene level, all
but three of our pathway modules were also present among those
identified from one or both of the published gene datasets (see
Fig. 4C). Ten pathway modules (angiogenesis, EGF, ERBB,
integrin signaling, long term potentiation, MAPK, natural killer
cell mediated toxicity, PDGF, regulation of actin cytoskeleton and
Figure 3. Determination of MDM2 copy number by FISH. The MDM2 gene was assayed in two melanoma samples (LAU-Me275 and LAU-T50B)
derived from the same patient. Panels A and C show a metaphase and B and D an interphase. MDM2 probe is in red; centromere-specific probe is in
green. FISH shows amplification for both LAU-Me275 (more than eight copies) and LAU-T50B (four copies). Metaphase-FISH helps to identify
homogeneously staining regions and Interphase-FISH to estimate the copy number.
doi:10.1371/journal.pone.0018369.g003
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between amplified genes in published melanoma datasets (Stark and Hayward 2007; Gast et al., 2010) and our list of over-expressed genes within
focal amplifications B. Intersection between genes within homozygous deletions from the Stark and Hayward and Gast et al. datasets and our list of
non-expressed genes within deletions C. Intersection between pathways found significantly affected by SCNAs from our analysis of the three
datasets.
doi:10.1371/journal.pone.0018369.g004
Table 3. Pathways identified by network-guided analysis.
Pathway #Melanomas Genes #genes
G protein signaling 6 ADORA1, ADRA2A, CHRM1, CHRM5, DRD2, GNAO1, GNB3, GNG4,
HTR1F, OPRL1, PLCB2, RGS10, RGS11, RGS14, RGS19
15
WNT signaling (includes Apoptosis and
Hedgehog signaling)
6 CDH19, CDH2, CDH4, DVL1, FRAT1, FZD8, PCDH17, PCDH9,
SFRP1, WNT11, WNT16, WNT2B, WNT4, WNT5B
14
Cadherin signaling 6 ACTG2, CDH19, CDH2, CDH4, FZD8, PCDH17, PCDH9, WNT11,
WNT16, WNT2B, WNT4, WNT5B
12
Melanogenesis 6 CAMK2A, CAMK2G, DVL1, FZD8, NRAS, WNT11, WNT16, WNT2B,
WNT4, WNT5B
10
Angiogenesis 5 BRAF, DVL1, EFNB2, EPHA3, EPHB2, FGF1, FRS2, NRAS, PIK3R3,
PRKCZ, SFRP1, WNT2B, WNT5B
13
Axon guidance (migration and adhesion) 5 CDK5, EFNB2, EPHA3, EPHB2, EPHB6, FES, NRAS 7
MAPK signaling 5 DUSP1, DUSP12, DUSP2, FGF1, FGF14, FGFR4, MAPK9 7
TGF beta signaling 5 ACVRL1, AMHR2, FOXH1, LEFTY1, SMAD9, TGFB1, TLL2 7
Alzheimer disease 5 CHRM1, CHRM5, PKN3, PRKCZ 4
FGF signaling 5 FGF1, FGF14, FGFR4, FRS2 4
Calcium signalling 4 CAMK2A, CAMK2G, CHRM1, CHRM5, GNAO1, GRIN2C, PRKCZ,
RGS10, RGS11, RGS14, RGS19
11
Huntington_disease (vesicle-mediated transport) 4 ACTG2, CLTB, GRIN2B, GRIN2C, GRIN3A, KALRN 6
Neuroreceptor (Muscarinic, Metabotropic) 4 GRIN2B, GRIN2C, GRIN3A, KCNQ2, PKN3, PRKCZ 6
Cell cycle (G1 progression) 4 CCNA1, CDC20, CDC26, CDKN2B, HDAC1 5
doi:10.1371/journal.pone.0018369.t003
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overlap with our pathway dataset was 66%. Thus, the majority of
pathways defined by SCNA affected genes in our melanoma
samples were recurrent in the three datasets, whereas the
individual genes were not.
An additional benefit of the protein network-guided approach is
that it generates a list of genes affected by SCNA that contributed
significantly to a given pathway (see Table S4). Although two-
thirds of the pathways were common between our dataset and the
published datasets, only two genes, NRAS and BRAF, were present
in all three (see Table S5). Of the genes shared by two datasets,
four were components of the angiogenesis pathway, including
EPHA3 and FRS2. We noted also that several members of the
WNT (WNT3A, 4, 5B, 7A, 9A, 11, 16) or cadherin (CDH2, 4, 9, 12,
17, 18, 19) gene families were affected by SCNA in only one
dataset, further reinforcing the idea that different genes can
potentially alter the same pathway (WNT or cadherin) in different
melanoma samples.
Discussion
Our goal to identify somatic copy number aberrations in
metastatic melanoma cell lines revealed extreme levels of
aneuploidy characteristic of this cancer type [21,22], and
complicated the application of standard CGH array protocols
[9,10,11]. Nevertheless, using our GMM method we were able to
demonstrate that although CGH arrays fail to identify all large-
scale amplifications, they are able to detect deletions very
efficiently, including genes having lost expression compared to
melanocytes (see Table 2 and Fig. S7). Conversely, SNP arrays,
which measure hybridization intensities for both alleles at
heterozygous loci, allow the consideration of an additional
parameter (the so-called B-allele frequency) and greatly improve
the measurement of DNA copies beyond the normal diploid
complement (as implemented in the OverUnder algorithm,
Attiyeh et al., 2009; see Fig. S6). We did notice, however, that
this algorithm systematically detected deletions located in sub-
telomeric regions for both tumors and controls, which indicates a
systematic bias and suggests that the algorithm is optimized to
detect duplications and amplifications but not deletions. There-
fore, it can be argued that CGH and SNP techniques should be
combined to obtain a reliable assessment of all copy number states
from deletion to high-level focal amplification.
To enrich for genes that might be involved in the oncogenic
process, we focused on two groups: focally amplifiedgenes that were
over-expressed relative to melanocytes; and deleted genes with no
expression in the melanoma cell lines, but that were expressed in
normal melanocytes. In the first group, MDM2 [5,17] was the only
cancer gene amplified and over-expressed in more than one
melanoma sample. Comparison of genes amplified in our samples
with published gene lists from two large melanoma studies (Stark
and Hayward 2007; Gast et al., 2010) while revealing very little
overlap (see Fig. 4) did identify BRAF, MDM2, and NRAS, genes
known to be important in melanoma [5,17,23,24,25,26,27,28,29].
In the second group, ten genes were deleted in three of the
melanoma samples (see Table S2). These genes are located on
Chr6q25, Chr6q27, Chr9 or Chr10p, consistent with previous
observations that both arms of chromosomes 9 and 10 and Chr6q
frequently undergo hemizygous deletion or copy neutral LOH in
melanoma[14]. Of the ten genes, the Parkinson’s disease-associated
gene PARK2 has been recently described asa tumor suppressor gene
inglioblastomaandothermalignancies[30], whileDLL1, HSD17B3
and ULBP have been reported to be associated with cancer,
although not as tumor suppressors [31,32,33,34,35,36,37]. Exper-
imental investigation will be required to determine if any of these
ten genes performs an anti-oncogenic function in melanoma cells.
The only deleted gene common to our study and those of Stark and
Hayward and Gast et al. was PTEN, a tumor suppressor gene
already known to be deleted in melanoma [7,38].
In an alternative approach to detect recurrent events in these
samples, we used a protein network-guided analysis
[20,39,40,41,42,43] to identify pathways affected by SCNA-genes
in the seven melanoma cell lines. In contrast to the low level of
recurrence in these melanoma samples at the individual gene level,
we found that six pathways were shared by five of the samples, and
four pathways (G protein, WNT, cadherin signaling and
melanogenesis) were common to six (see Table 3). Several of
these pathways are highly relevant to melanoma (e.g. MAPK,
cadherin and FGF signaling) and have also emerged from cDNA
expression studies [44], lending support to our results. G proteins
transduce signals from G protein-coupled receptors (GPCRs), the
largest family of membrane receptors involved in signal transduc-
tion, and whose over-expression in tumors can contribute to tumor
progression, angiogenesis and metastasis [45]. Alteration of G
proteins could impact the activities of GPCRs key to melanocytic
cells, such as MC1R (melanocortin receptor), chemokine (e.g.
CXCR2), and endothelin receptors. [46]. The recent identification
of activating mutations in two G protein alpha subunits, GNAQ
and GNA11, in a large proportion of uveal melanomas [47,48],
further underscores the relevance of this class of proteins to
melanoma.
Although annotated as distinct pathways, WNT, cadherin
signaling and melanogenesis shared six SCNA-genes in common
(FZD8 and several members of the WNT family). This may reflect
interactions between these pathways, an interplay between the
WNT and cadherin pathways is known to exist [49], or may be a
consequence of poor pathway annotation. The cadherin pathway
controls cell-adhesion and plays a role in invasion and metastasis
[50]. WNT (and Hedgehog) control development and growth in
the embryo; aberrant activation of their transcriptional compo-
nents ultimately affects cell fate, proliferation, and migration
[51,52,53]. The only common non-signaling pathway was
melanogenesis. Melanoma develops from melanocytes, cells highly
specialized in the synthesis of melanin pigment, a process that
requires a complex enzymatic machinery and unique organelle
structures [54]. Our pathway analysis predicted that melanoma
SCNA affect melanogenesis. Loss of pigmentation in metastases
compared to primary tumors is commonly observed in cutaneous
melanoma, and although not completely understood, it can be
brought about by different mechanisms, such as premature
degradation of melanogenic proteins [55] or downregulation of
MITF transcription program [56]. Our study suggests that SCNA
may also contribute to these alterations. An unexpected pathway
that emerged from our analysis, and perhaps merits further
exploration, is neurotransmission. These results suggest an
involvement of neuronal pathways in melanoma, possibly related
to the neural crest origin of melanocytes. Lending support to this
hypothesis, the metabotropic glutamate receptor GRM1 has
recently been implicated in the development of spontaneous
melanoma in a mouse model, and an autocrine glutamate/GRM1
loop has been described in human melanoma [57].
Comparison of the pathways generated from SCNA-genes in
our data and genes affected by copy number changes in two
published datasets (Stark and Hayward [14] and Gast et al. [13])
revealed a high level of overlap, much higher than we expected
based on the number of commonly affected genes (see Fig. 4). An
explanation for this outcome is that different genes within the same
pathway are affected in different datasets, and the commonalities
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genes in a given pathway would be expected to increase with
increasing sample size, and this is largely the case between our
data and those of Stark and Hayward, but not in the Gast et al
dataset (see Table S4). The reason for the low number of SCNA
affected genes and corresponding pathways in the latter case may
be the high stringency criteria employed in their analysis [13].
The angiogenesis pathway was one of ten common to all three
datasets. Its up-regulation is a well-known hallmark of cancer [58],
and it has long been proposed as a target for therapeutic treatment
[59,60]. Activation signals for angiogenesis include vascular
endothelial growth factor (VEGF) and acidic fibroblast growth
factor (FGF), and both were in our list of significantly affected
pathways (see Table 3) and within our analysis of the Stark and
Hayward (VEGF and FGF) and Gast et al (VEGF) datasets (see
Table S4). Two genes in this pathway, EPHA3 and FRS2, were
designated SCNA-genes in both our dataset and in Stark and
Hayward, and were annotated as amplified, in skin-derived
tumors, in the Cancer Genome Project dataset [5,61].
In our analysis EPHA3, an ephrin tyrosine kinase receptor, was
both focally amplified and over-expressed only in LAU-Me275.
However, EPHA3 was highly over-expressed in LAU-T149D and
LAU-Me246 (see Table S3) and amplified in LAU-T618A
(CN=6.4), LAU-Me235 (CN=4) and LAU-T50B (CN=4.2).
EPHA3 is recurrently mutated in adenocarcinoma [62,63] and has
been implicated in renal carcinoma, glioblastoma, colorectal,
breast and lung cancer [63,64,65,66,67]. Mutations in EPHA3
have been detected in melanoma [68], and several ephrin-derived
peptide antigens (from EPHA2, EPHA3 and EPHB6) can be
recognized by cancer-specific cytotoxic T-cells [69,70,71,72]. In
addition, the feasibility of specific EPHA3 targeting has been
reported [73]. These observations indicate that EPHA3 might be a
promising target for therapeutic treatment in melanoma and other
cancers.
FRS2, fibroblast growth factor receptor substrate 2, is an
adaptor that acts downstream of a limited number of receptor
tyrosine kinases, in particular FGF and neurotrophin receptors,
RET and ALK, and plays a major role in tumorigenesis [74]. Dey
and coworkers [75] recently targeted the FGF receptors (FGFR)
using tyrosine kinase inhibitors to decrease the activity of AKT
and ERK kinases, inducing apoptosis in breast cancer cell lines.
FGFR inhibition is highly relevant to melanoma, where autocrine
stimulation via FGF2/FGFR1 constitutes a pivotal role in
proliferation and survival [76]. FRS2 has been suggested as a
therapeutic target in cancer [77] and because of its downstream
activities to FGFR and other receptors, it might offer new insights
in melanoma treatment. In our data FRS2 was both focally
amplified and over expressed in two melanoma samples (LAU-
T149D and LAU-Me275) and amplified (CN=4) in two
additional melanomas (LAU-T618A and LAU-Me235). Inspec-
tion of its amplification status in larger melanoma collections
would be useful to confirm its potential role as a target of interest
in melanoma.
Using SILAC, we demonstrated a global correlation between
mRNA and protein levels across all samples. However, we are
aware that the levels of individual proteins may not always reflect
mRNA levels, and that the activity of certain proteins, and
therefore the activation state of cellular pathways, can be further
modulated by post-translational modifications. Further investiga-
tions, beyond the scope of the current study, will be required to
address these possibilities. Such studies should include a functional
assessment of the implicated pathways using various manipulations
to activate or inhibit them (e.g. with siRNA or other inhibitors) to
determine the role of the pathways in these melanoma cell lines.
In conclusion, we have identified SCNA-genes and pathways
potentially altered in our metastatic melanoma samples and two
published datasets (Stark and Hayward 2007; Gast et al., 2010)
which should be investigated by screening larger tumor collections
and in functional studies. Two SCNA-genes, EPHA3 and FRS2,
emerged from our analysis as potential therapeutic targets. These
genes were replicated in our analysis of the two published
melanoma collections, have been extensively studied in other
cancer types, and thus might offer new insights in the treatment of
malignant melanoma.
Materials and Methods
Melanoma samples, DNA and RNA extraction
Melanoma cell lines were established from metastases from
patients with cutaneous melanoma and were used at low passage
(,10). Donor matched cells were either peripheral blood
lymphocytes (PBL) or Epstein-Barr virus transformed lymphoblas-
toid (EBV) cell lines. EBV cell lines were karyotyped to ensure
genome stability and diploidy. Approval to use these samples for
this project was given by the CHUV (Centre Hospitalier
Universitaire Vaudois) ethical committee for clinical research.
Melanoma cell lines were cultured conditions in RPMI-1640
medium supplemented with 10% fetal calf serum (FCS), and no
antibiotics. Human foreskin melanocytes were grown in HAM-
F10 medium supplemented with 2% FCS, 5% MelanoMax
supplement (Gentaur, Belgium) and 6 mM HEPES. EBV cell lines
were cultured in IMDM/10% FCS medium. All cultures were
without mycoplasma. DNA (Gentra kit, Qiagen) and RNA
(guanidinium/cesium chloride gradient) isolation and karyotype
preparations were performed from parallel cultures.
Cytogenetic and FISH analysis
Cytogenetic (GTG-banding) and fluorescence in situ hybridiza-
tion (FISH) metaphase analyses of melanoma cell lines were
performed using standard protocols. We performed 15 spreads for
each melanoma cell line, except for Lau-Me246 [14] and Lau-
Me275 [21]. Dual color FISH was done using a commercially
available set consisting of a locus-specific MDM2 combined with a
chromosome 12 centromeric probe (Kreatech Poseidon FISH
probe) to distinguish aneuploidy of chromosome 12 and specific
locus loss or gain. Chromosomes with homogeneously staining
region (HSR) were identified with the analysis of FISH metaphases
in inverted digital images. Copy number estimation of HSR was
done using FISH interphases.
Comparative genomic arrays (CGH)
CGH arrays were processed according to the manufacturer’s
protocol (Agilent Technologies, Inc.) and as described in Martinet
et al. [78].
The normalization and detection of copy number aberration is
detailed in Methods S1. In brief, signal intensities were normalized
using three independent normalization schemes: Loess [79];
PopLowess [80]; and the statistical framework from Chen et al.
[15].
Then probe-level data were segmented using Circular Binary
Segmentation [81,82] and attributed a discrete copy number to
segments using three independent methods: 1) a naive scoring-
based approach, where outliers relative to the chromosomal
baseline are detected using a non-parametric score; 2) the
MergeLevels method [83] and 3) our own classification algorithm
based on Gaussian Mixture Model which models the observed
distribution of intensity ratios as a combination of Gaussian
distributions that can be subsequently classified into deletion
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tion (CN=3 and CN$4) (see Fig. S3).
Single Nucleotide polymorphism arrays (SNP)
Illumina 1M SNP arrays. Genomic DNA from each of the 7
melanoma and their matched normal cells (either EBV cell line or
PBL); as well as two control melanocytes were genotyped on the
Illumina Infinium Human1M-Duo arrays. Aliquots of DNA (30 ml
at 50 ng/ml) for each sample were processed according to the
manufacturer’s protocol (Infinium HD Gemini protocol).
Subsequently we used the OverUnder algorithm [16] to correct
the hybridization log ratios for polyploidy and to attribute a
continuous copy number value to each SNP. We estimated that
the window size parameter set to 201 SNPs, gave the highest
reproducibility between technical replicates (see Fig. S5A and
S5B).
Affymetrix 6.0 arrays. As part of the technical replicate
design, we analyzed LAU-Me275 on Affymetrix 6.0 SNP arrays.
The experiment was performed in accordance with the
manufacturer’s instructions. Normalization and copy number
prediction were done using the PICNIC algorithm [84].
Transcriptome sequencing
The transcriptome from all seven melanoma as well as a pool of
two melanocytes was sequenced using the Roche 454 Titanium
technology. mRNA isolation and cDNA preparation were
performed following the protocol used by Bainbridge et al. [85],
with some modifications (See Methods S1). 3–5 mg of cDNA were
used for 454 libraries preparation, according to manufacturer’s
protocol. All experiments produced about 1M single end reads,
with a median length of 367 nucleotides (interquartile range 265–
436). We derived transcript tag counts using our own published
methodology [86] (see also Methods S1). Using tag counts from
the pool of melanocytes, we were able to derive a ratio of
expression for each melanoma with respect to these control
melanocytes.
Detection of somatic copy number alterations with
altered expression (SCNA-genes)
We computed the median copy number at each Refseq gene.
To overcome density limitations, we included SNPs that were
within 2 kb of the gene boundaries. For CGH arrays, we included
probes within 3 kb of the gene boundaries. We defined SCNA-
genes as follows. A gene was flagged as within a focal amplification
when its CN, as computed from SNP arrays, was $4, the
difference in CN relative to the chromosomal arm was $1, the
gene was diploid (CN=2) in the matched control cell line, and the
expression in the melanoma cell line was at least 2-fold greater
than that in the control melanocytes. For deletions, a gene needed
to have CN,2, as detected by CGH, without expression in the
melanoma cell line and CN=2 with detected expression in the
melanocytes.
Protein network-guided analysis of SCNA
A non-redundant human protein interaction network was
generated by combining iRefseq [87] and Pathway Commons
[88] protein interaction databases with functional interactions
from Panther pathways [89]. The resulting network has 21,876
nodes and 376,528 edges and combines interaction data from 15
primary protein interaction databases (BIND, BioGRID,
CORUM, DIP, HPRD, IntAct, MINT, MPact, MPPI, OPHID,
Reactome, HumanCyc, Cancer Cell Map, IMID and NCI/
Nature pathway interaction database). Mapping between gene
names and their protein Uniprot IDs was downloaded from the
HGNC website (www.genenames.org). Among the 1710 (unique)
SCNA-genes, 104 did not have a UniProt ID and 43 could not be
mapped onto the network. Using a walk trap community
algorithm and permutation approaches (with n=1000), we were
able to extract clusters of proteins from the network (Details are
available in Methods S1).
Pathway analysis
Significance of overlap between the modules and pathways from
Panther, Kegg and MSigDB [89,90,91] was calculated with an
hypergeometric test, P-values were corrected for multiple
comparisons by calculating the false discovery rate using the
Benjamini and Hochberg procedure [92].
To reduce the redundancy present in pathway database
annotation, we first combined pathways that contained the same
SCNA-genes from the same melanoma cell lines, then we
reviewed the pathway list to either remove redundancies or un-
merge unrelated pathways affected by similar genes. We also
excluded KEGG ‘‘cancer’’ annotated pathways.
Proteomic analysis
SILAC. Cell growth conditions and labeling are detailed in
Methods S1. LC-MS/MS data were analyzed using Mascot 2.2
(Matrix Science, London, UK) for database search and MaxQuant
1.0.13.13 for peak list export from raw data and quantitative
analysis [93]. Database search was carried out against the IPI
human database (version 3.52, [94]) including decoy sequences
and a list of common contaminants. A maximum false discovery
rate of 1% was used for protein identification.
A total of 5522 proteins were detected by the SILAC
experiment. We excluded 55 proteins that matched the list of
common contaminants. To check whether culture condition (with
the heavy isotope) could influence the protein quantification, we
performed a self-self experiment with LAU-Me275. Although no
significant bias was found (see Fig. S9), we excluded 79 proteins
that were outliers in this experiment. Next, we checked the
number of peptides detected per protein (see Fig. S10). Since
protein quantification is not accurate when only few peptides are
observed, we excluded 2,134 proteins that had less than three
peptides and 42 with missing values in all seven experiments. This
led to a cleaned dataset of 3,212 proteins; 2,922 of them could be
remapped to Refseq genes using their Uniprot ID and were used
for subsequent comparison with RNA-seq data.
Comparison with RNA-seq data. For comparison, we
normalized the RNA seq tag count in the same manner as the
SILAC data (i.e. we expressed the transcript tag count from LAU-
Me275 with respect to all other samples, including the control
melanocytes). Next, we computed the Spearman correlation
coefficient between the expression and protein log2 ratios (see
Fig. S11). P values to test for significantly positive correlation were
estimated using large-sample approximations (as implemented by
the ‘corr’ function in MATLAB).
Accession number
Microarray and sequencing data were deposited in NCBI GEO
and are available under accession number GSE23056.
Supporting Information
Figure S1 CGH hybridization ratio in a tetraploid
region in LAU-Me275. Each plot shows the hybridization
log2 ratio at each CGH probe (in gray) obtained using three
normalization methods. Ridge refers to the framework from Chen
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Segmentation. Karyotype analysis of LAU-Me275 revealed 11q
amplification (CN$4), so the expected CGH log ratio would be
two. Here the ratios obtained from three different normalizations
failed to reflect the amplification (both Loess and Ridge were close
to 0; PopLowess was close to 0.6 indicating 3 copies).
(DOC)
Figure S2 Correlation between replicates using differ-
ent normalization schemes. The scatter plots illustrate the
correlation at each CGH probe between two replicates. The
heatmaps show the correlation for each pairs of replicates. The
normalization method is indicated in each plot title. RIDGE refers
to the framework from Chen et al.
(DOC)
Figure S3 Gaussian Mixtures identified in four repli-
cates from LAU-Me275. Each histogram shows the distribution
of CBS segment log2 ratios, colors highlight the Gaussian
components. The number of components identified and the Bayes
Information Criterion are indicated in each figure title.
(DOC)
Figure S4 Comparison of CNV detection algorithm on
CGH data. Panels are, from left to right: a melanoma with large
deletions (LAU-Me280); a melanoma with large amplifications
(LAU-Me275); and a control EBV cell line (male) hybridized using
a pool of female references. From top to bottom: CNV
classification (following CBS segmentation) using 1) Gaussian
Mixture Model (GMM), 2) MergeLevels, 3) the scoring-based
approach. Each dot corresponds to a CGH probe with its genomic
position on the X axis and its log2 ratio of hybridization on the Y
axis. Colors indicate the copy number state: orange,=1 copy
gray=2 copies, cyan=3 copies and dark blue more than 3 copies.
For the scoring approach distinction is made between 1 copy
(orange) and 0 copy (red).
(DOC)
Figure S5 Optimization of Illumina analysis and com-
parison with Affymetrix prediction in LAU-Me275.
A. Pearson correlation between SNP CN, as a function of
OverUnder window size. B. Copy number concordance at each
SNP for different window sizes of OverUnder. Colors indicate
window size parameters, the bar height indicates the total number
of SNPs (in log10 scale) found in one replicate. The gray bar
indicates the intersection between two technical replicates. The
percentage of concordance (number of SNPs found with the same
copy number bin in both replicates/total number of SNPs from
this given copy number bin in the first replicate) is shown on top of
each bar. C. Copy number prediction on chromosome 1 using
OverUnder with a window size of 201 SNPs. D. Copy number
prediction on chromosome 1 using an Affymetrix 6.0 array (with
the PICNIC algorithm).
(DOC)
Figure S6 Copy number analysis using Illumina SNP
arrays. DNA from LAU-Me275 was hybridized to Illumina SNP
arrays, and the data were analyzed using the method of Attiyeh et
al. The top panel shows genome-wide copy number: dark blue
indicates more than three copies; cyan:three copies; gray:copy
neutral; orange: deletion. Subsequent panels show chromosome 7
with, from top to bottom: Hybridization log2 ratio; B allele
frequency; and copy number prediction.
(DOC)
Figure S7 Intersection between CGH and SNP predic-
tions. A. Intersection between CGH and SNP predictions for
genes with more than 4 copies. B. Intersection for genes within
deletions. C. Intersection for genes within deletions for which
expression was not detected.
(DOC)
Figure S8 Copy number prediction from CGH and SNP
arrays, LOH prediction from SNP arrays.
(PDF)
Figure S9 Boxplots of SILAC heavy/light normalized
log2 ratios. In all experiments, LAU-Me275 was labeled with
the heavy isotope; the unlabeled sample is indicated in the boxplot
label on the X axis. ‘NHM’ refers to the pool of normal
melanocytes and ‘self-self’ to a control experiment using only
LAU-Me275 to check for any bias due to the label/no label
culture conditions (no significant bias was detected).
(DOC)
Figure S10 Histogram of unique peptides identified per
protein in the SILAC data.
(DOC)
Figure S11 Correlation between mRNA expression and
protein levels. Both SILAC and RNA seq log2 ratios are
expressed for LAU-Me275 with respect to the sample indicated in
each plot title. Spearman Rho correlation coefficient is also
indicated in the title. In all experiments, the correlation is
significantly positive (p,0.001).
(DOC)
Table S1 Count of genes affected by SCNA.
(DOC)
Table S2 Processed list of SCNA genes in all seven
melanoma cell lines.
(XLS)
Table S3 Genomic and transcriptomic data for SCNA-
genes in all seven melanoma cell lines.
(XLS)
Table S4 List of pathways significantly enriched in
SCNA, and pathway comparison between three melano-
ma datasets.
(XLS)
Table S5 List of genes contributing to pathway enrich-
ment in three melanoma datasets.
(XLS)
Methods S1
(DOC)
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